Clinical Trial Detail

NCT ID NCT04188951
Title HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Henry Ford Health System
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.